Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.56 |
| ▸ | CSF1R | P07333 | 10/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490930 | 0.92 | CSF1R (0.66) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4495316 | 0.90 | PDGFRB (0.55) | PDGFRBCSF1RKDRDDR2FLT3 | |
| SCHEMBL4498690 | 0.90 | KDR (0.53) | PDGFRBCSF1RKDRDDR2FLT3 | |
| SCHEMBL4491172 | 0.89 | PDGFRB (0.63) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL5591912 | 0.87 | PDGFRB (0.50) | PDGFRBCSF1RKDRDDR2FLT3 | |
| SCHEMBL2174214 | 0.85 | PDGFRB (0.66) | PDGFRBCSF1RKDRDDR2FLT3 | |
| SCHEMBL4494188 | 0.85 | PDGFRB (0.67) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL5617932 | 0.84 | CSF1R (0.53) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4503951 | 0.84 | CSF1R (0.51) | PDGFRBCSF1RKDRDDR2FLT3 | |
| SCHEMBL4514278 | 0.83 | KDR (0.53) | PDGFRBCSF1RKDRDDR2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | PDGFRB 1820/4885CSF1R 588/4885KDR 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.